---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000045"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T15:52:18.983732+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance

## Summary
- GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.
- Prenatal revenue grew 11% YoY; Pharmacogenomics revenue fell 20% due to UnitedHealthcare coverage cut for GeneSight.
- Gross margin 69% (+40 bps YoY) on lab efficiencies; operating loss $29M vs $27.9M YoY.
- Updated FY2025 revenue guidance lowered to $807-823M from $840-860M; adjusted EPS now $(0.02)-$0.02.
- CEO cited challenges in GeneSight and unaffected hereditary cancer; taking steps to reduce costs and drive growth.

## SEC filing metadata
- accession: 0000899923-25-000045
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000045/0000899923-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000045/mygn-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000045
- JSON: https://secwatch.observer/filing/0000899923-25-000045.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.